Head-to-Head in Heart Failure: Comparative Insights on Empagliflozin and Dapagliflozin
Heart failure (HF) remains a leading cause of morbidity and mortality globally, with increasing prevalence driven by aging populations and comorbidities such as diabetes mellitus. Recent advances have highlighted sodium-glucose cotransporter-2 (SGLT2) inhibitors, particularly empagliflozin and dapag...
Furkejuvvon:
| Váldodahkkit: | , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
MDPI AG
2025-10-01
|
| Ráidu: | Biomedicines |
| Fáttát: | |
| Liŋkkat: | https://www.mdpi.com/2227-9059/13/10/2422 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|